Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Movantik for Opioid-Related Esophageal Disorders
NCT02998606Phase 2Terminated
- Sponsor
- Temple University
- Start
- Jan 2017
- Primary completion
- Oct 2018
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naloxegol in opioid-induced esophageal dysfunction (OIED) (2 arms), sponsored by Temple University. Primary endpoint: Manometric improvement in Integrated Relaxation Pressure at 28 days. Started Jan 2017; status: terminated.
02
Drugs
naloxegol
03
Conditions
opioid-induced esophageal dysfunction (OIED)
Beyond the preview
Go deeper on NCT02998606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998606.